234 related articles for article (PubMed ID: 21514606)
21. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
22. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
23. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
Dinarello CA
J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
[TBL] [Abstract][Full Text] [Related]
24. [Descriptive study of infectious complications in 109 consecutive liver transplant recipients].
García-Prado E; Cordero E; Alamo JM; Gómez MA; Pascasio JM; Sánchez M; Cisneros JM
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):199-205. PubMed ID: 19361893
[TBL] [Abstract][Full Text] [Related]
25. Biologics and infections: lessons from tumor necrosis factor blocking agents.
Wallis RS
Infect Dis Clin North Am; 2011 Dec; 25(4):895-910. PubMed ID: 22054762
[TBL] [Abstract][Full Text] [Related]
26. [Fatal infection in patients with systemic lupus erythematosus and incidence, types, predisposing factors, and prevention--comparative study of patients with rheumatoid arthritis and primary nephrotic syndrome].
Nakabayashi K; Arimura Y
Nihon Rinsho; 1990 Oct; 48(10):2326-32. PubMed ID: 2280479
[No Abstract] [Full Text] [Related]
27. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
28. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
29. [Infectious events during the first year of treatment with an antagonist of the tumor necrosis factor].
Gulín Dávila J; González-Gay MA
Farm Hosp; 2013; 37(5):351-7. PubMed ID: 24128096
[TBL] [Abstract][Full Text] [Related]
30. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
31. [The pulmonological manifestations of rheumatoid arthritis].
Bernscherer G; Karabélyos C; Tarján Z
Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
[TBL] [Abstract][Full Text] [Related]
32. [Infections in patients affected by rheumatologic diseases associated to glucocorticoid use or tumor necrosis factor-alpha inhibitors].
Fica A
Rev Chilena Infectol; 2014 Apr; 31(2):181-95. PubMed ID: 24878907
[TBL] [Abstract][Full Text] [Related]
33. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
Gómez-Reino J; Carmona L
Acta Reumatol Port; 2006; 31(3):201-3. PubMed ID: 17094331
[No Abstract] [Full Text] [Related]
34. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
35. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.
Kourbeti IS; Ziakas PD; Mylonakis E
Clin Infect Dis; 2014 Jun; 58(12):1649-57. PubMed ID: 24647016
[TBL] [Abstract][Full Text] [Related]
36. [Early infection in liver transplant recipients: incidence, severity, risk factors and antibiotic sensitivity of bacterial isolates].
Losada I; Cuervas-Mons V; Millán I; Dámaso D
Enferm Infecc Microbiol Clin; 2002 Nov; 20(9):422-30. PubMed ID: 12425875
[TBL] [Abstract][Full Text] [Related]
37. [Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports].
Söderlin M; Blomkvist C; Dahl P; Forsberg P; Fohlman J
Lakartidningen; 2005 Dec 5-11; 102(49):3794-6, 3799-800. PubMed ID: 16408703
[TBL] [Abstract][Full Text] [Related]
38. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
39. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.
Carmona L; Descalzo MA; Perez-Pampin E; Ruiz-Montesinos D; Erra A; Cobo T; Gómez-Reino JJ;
Ann Rheum Dis; 2007 Jul; 66(7):880-5. PubMed ID: 17324968
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor blockade and the risk of viral infection.
Kim SY; Solomon DH
Nat Rev Rheumatol; 2010 Mar; 6(3):165-74. PubMed ID: 20142812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
